Broken Records and Red Eyes - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Broken Records and Red Eyes

Pharmaceutical Technology

Records R'nt Us

It was, our GMP Agent-in-Place recalls, a typical, small, clinical-type facility... managed in the typical, informal way. High employee turnover and lax financial record-keeping finally caught the attention of off-site management, which ordered a financial audit. "The audit did turn up financial irregularities," says the Agent, "and it raised serious questions about the site's GMP record-keeping, so we started reviewing those, too. The icing on the cake was a facility cleaning record, signed by the same employee on 30 consecutive days... all with the same pen, and including 15 days when the pay records indicated that he'd been on vacation. So either the employee was cooking the cleaning records, which was illegal, or he had worked more than 21 days in a row without a day off and falsified pay records, which were both illegal.

"Management called in the FDA, who sent an investigator to 'help' with our internal review. So we had two auditors and an FDA inspector in the same small facility simultaneously, poring over records. At the end of each day, we would get together, share our audit findings with each other, and shake our heads.

"In the end," our Agent-In-Place notes, "we took marketplace action for the product, fired all the staff, and closed the site. And we didn't lose any time before auditing all of the other similar sites in our network for similar deficiencies. Thank goodness, this one was unique. FDA issued a warning letter for lousy records, of course, but that was the end of it."

I 'speckt so

The maker of an injectable drug product used a dry powdered raw material, purchased in bulk and added to multiple batches.

Midway through the drum, process operators adding the raw material to the batch noticed small, black specks in the blend, says the GMP Agent-in-Place on the scene. The manufacturer immediately quarantined the earlier finished batches and initiated an investigation.

"After an extensive study, including examination of hundreds of raw-material drums and hundreds of hours of analytical work, the investigators determined that the particles were flecks of carbon," the Agent says. "Since they weren't soluble in the water we used as a solvent in the final product, normal filtration removed them, so the finished product was not adulterated.

"Of course, every batch of raw materials contains some impurities, though most are not visible. Our carbon specks accounted for less than 10 parts per million of raw material: there would be only a few particles in any 5 kg sample...very rare and very hard to see.

"Eventually, we determined that the particles were actually the raw material itself, carbonized during the extraction process. Since they posed no threat, our solution was to work with the vendor to establish an appropriate specification for the raw material, one that included low levels of 'discolored impurities.'"

It made me want to cry

"It was a nightmare," reports a GMP Agent-in-Place whose company made a liquid ophthalmic product. "Suddenly our customers began complaining about pain and burning of the eyes after using our product. We made 200,000 containers in a batch, and all the recent batches had been affected."

"Right away, we set up a crash program to investigate, testing the product exhaustively and matrixing all ingredient batches and materials.

"Someone suggested that the plastic container might be responsible, and we traced down all of the components of the container, closures, and seals.

"We followed the trail to the company that molded the plastic bottles, and from there to the company that supplied the resin to the bottle-maker. It turned out that the resin supplier had changed the colorant they used, without telling anybody down the line. And the colorant was leaching out of the container and irritating the customers' eyes.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here